This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Phosphofructokinase muscle (PFKM; PFK1)	<p>Patient sample and mouse studies suggest inhibiting glycosylation of PFK1 could help treat cancer. In samples from patients with breast and lung cancer, PFK1 glycosylation levels were two- to fourfold higher than those in adjacent normal tissues. In mice, injection of human non-small cell lung cancer (NSCLC) cells expressing a glycosylation-deficient S529A mutant <i>PFK1</i> led to formation of smaller tumors than injection of NSCLC cells expressing wild-type <i>PFK1</i>. Next steps include developing and evaluating small molecules that mimic the effects of inhibiting PFK1 activation.</p> <p>SciBX 5(35); doi:10.1038/scibx.2012.921 Published online Sept. 6, 2012</p>	Provisional patent application filed; available for licensing from the California Institute of Technology Office of Technology Transfer	<p>Yi, W. <i>et al. Science</i>; published online Aug. 24, 2012; doi:10.1126/science.1222278 Contact: Linda C. Hsieh-Wilson, California Institute of Technology, Pasadena, Calif. e-mail: lhw@caltech.edu</p>